Journal of Cancer Research and Therapeutics

SYSTEMATIC REVIEW
Year
: 2021  |  Volume : 17  |  Issue : 6  |  Page : 1297--1306

Pulmonary anaplastic large-cell lymphoma: A case-based systematic review of world literature


Somanath Padhi1, Manoj Kumar Panigrahi2, Sonali Mohapatra3, Pritinanda Mishra1, Susama Patra1, Mukund Namdev Sable1, Bhaskar Thakur4, Mamita Nayak5, Ashutosh Panigrahi3 
1 Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
2 Department of Pulmonary Medicine, Critical Care, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
3 Department of Medical Oncology/Hematology, Critical Care, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
4 Department of Biostatistics, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India
5 Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar; Department of Oncopathology, Acharya Harihar Regional Cancer Institute, Cuttack, Odisha, India

Correspondence Address:
Sonali Mohapatra
Department of Medical Oncology/Hematology, All India Institute of Medical Sciences, Bhubaneswar, Odisha
India

We describe a case of ALK1 negative (–) pulmonary anaplastic large-cell lymphoma (pALCL) in an adult female with an unfavorable outcome following combination chemotherapy and present a systematic review of 39 such sporadic cases reported over the past 28 years (1990–2018). pALCL occurred in 26 males and 13 females (median age, 43 years [5–81]) and 13/39 (33.33%) were ≤18 years. The lesions were endobronchial in 21 (53.85%) and parenchymal in 18 (46.15%) cases. Twenty-six cases were ALK1-; 13 were ALK1+ (positive); and 27/34 cases had a T cell phenotype (where tested). ALK- cases were characterized by higher age (P = 0.012) at presentation, more B symptoms (P = 0.002), and more parenchymal than endobronchial lesions (P = 0.039). The median survival (N = 29/39) was 60 months; pediatric group had a better survival than adult/elderly group (log-rank, P = 0.026). pALCL is rare and may have a distinct biological behavior.


How to cite this article:
Padhi S, Panigrahi MK, Mohapatra S, Mishra P, Patra S, Sable MN, Thakur B, Nayak M, Panigrahi A. Pulmonary anaplastic large-cell lymphoma: A case-based systematic review of world literature.J Can Res Ther 2021;17:1297-1306


How to cite this URL:
Padhi S, Panigrahi MK, Mohapatra S, Mishra P, Patra S, Sable MN, Thakur B, Nayak M, Panigrahi A. Pulmonary anaplastic large-cell lymphoma: A case-based systematic review of world literature. J Can Res Ther [serial online] 2021 [cited 2022 Jan 21 ];17:1297-1306
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2021;volume=17;issue=6;spage=1297;epage=1306;aulast=Padhi;type=0